A momentous convergence of industry, agriculture, and cutting-edge innovation is set to redefine Uganda’s economic landscape and significantly bolster its role in African pharmaceutical security. On November 20, 2025, H.E. President Yoweri Museveni will commission the DEI BioPharma Ltd Namasagali Plant in the Busoga region, marking the arrival of a multibillion-dollar facility that champions homegrown science and rural empowerment.
This investment is more than a factory; it is a profound symbol of Uganda’s capability to build its own biotech future and drive a sustainable green-energy transition, while strategically positioning the country as a key player in Africa’s pharmaceutical manufacturing sector.
The core innovation of the DEI BioPharma plant, according to Dr. Mathias Magoola, the Managing Director, lies in its feedstock. “The facility will utilise cassava grown by local farmers across Busoga as its primary raw material. This strategic pivot redefines cassava, once seen primarily as a humble food crop, as a valuable industrial resource that brings new dignity and income to Ugandan households,” Dr. Magoola noted.
He explained that the facility aims to produce three critical outputs that simultaneously address national needs in health, energy, and food security, which include:
- Pharmaceutical-Grade Ethanol: Essential for the production of medicines and disinfectants, directly supporting national health security and positioning Uganda as a reliable source of key pharmaceutical inputs and reducing reliance on imports.
- Bio-Starch: A versatile industrial ingredient used across various manufacturing sectors.
- Green Biofuels: Sustainable energy sources that power both medicine production and contribute to Uganda’s transition towards energy independence.
According to Dr. Magoola, the DEI BioPharma project embodies a holistic development model that links rural communities directly to high-value industrial output, ensuring that economic growth is inclusive and widely shared. He stressed that, being located in the eastern region of Uganda, the facility represents:
By producing pharmaceutical-grade inputs locally, the plant helps to de-risk Africa’s medical supply chains and provides the foundational ingredients necessary for broader drug manufacturing across the continent.
By creating a massive, stable market for local cassava farmers, the project guarantees income streams, strengthens the agricultural value chain, and uplifts the Busoga community.
The production of green biofuels signifies a commitment to environmentally conscious energy generation, aligning with global climate goals.
The entire operation, from Busoga’s farmlands to DEI BioPharma’s laboratories, is a powerful narrative of Uganda’s resilience, ingenuity, and unwavering belief in its own scientific capabilities. Just as Dr. Magoola reiterated, the commitment driving this project is clear: a future where “every harvest fuels health, every innovation creates opportunity, and every Ugandan can proudly say ‘This is made in Uganda.’”
The commissioning of the Namasagali Plant is thus the start of a transformative chapter for Uganda’s bio-economy and its stature in African health security.